| [1] |
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J]. Lancet, 2013, 381 (9863): 303-312.
|
| [2] |
Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress [J]. Nat Rev Cancer, 2012, 12(2): 89-103.
|
| [3] |
Gayyed MF, Abd E-Maqsoud NM, El-Hameed El-Heeny AA, et al. c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases [J]. J Gastrointest Oncol, 2015, 6(6): 618-627.
|
| [4] |
Gao H, Guan M, Sun Z, et al. High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis [J]. Tumour Biol, 2015, 36(2): 515-520.
|
| [5] |
Sun YL, Liu WD, Ma GY, et al. Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis [J]. Int J Med Sci, 2013, 10(5): 548-559.
|
| [6] |
Isella C, Mellano A, Galimi F, et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases [J]. Ann Surg, 2013, 257(6): 1089-1095.
|
| [7] |
Liska D, Chen CT, Bachleitner-Hofmann T, et al. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation [J]. Clin Cancer Res, 2011, 17(3), 472-482.
|
| [8] |
Song N, Liu S, Zhang J, et al. Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells [J]. Int J Mol Sci, 2014, 15(4): 5838-5851.
|
| [9] |
Kang YK, Muro K, Ryu MH, et al. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer [J]. Invest New Drugs, 2014, 32(2): 355-361.
|
| [10] |
Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer [J]. J Clin Oncol, 2011, 29(24): 3307-3315.
|
| [11] |
De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J]. Lancet Oncol, 2010, 11(8), 753-762.
|
| [12] |
Corso S, Giordano S. Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective [J]. Cancer Discov, 2013, 3(9): 978-992.
|
| [13] |
Dulak AM, Gubish CT, Stabile LP, et al. HGF-independent potentiation of EGFR action by c-Met [J]. Oncogene, 2011, 30(33): 3625-3635.
|
| [14] |
Varkaris A, Gaur S, Parikh NU, et al. Ligand-independent activation of MET through IGF-1/IGF-1R signaling [J]. Int J Cancer, 2013, 133(7): 1536-1546.
|
| [15] |
Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer [J]. N Engl J Med, 2014, 371(23): 2167-2177.
|
| [16] |
Scagliotti G, von Pawel J, Novello S, et al. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer [J]. J Clin Oncol, 2015, 33(24): 2667-2674.
|
| [17] |
Eng C, Bessudo A, Hart LL, et al. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy [J]. Int J Cancer, 2016, 139(1): 177-186.
|